Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENB-RIGGS for small lung tumors
NCT02570958Phase 1Withdrawn
- Sponsor
- St. Joseph's Healthcare Hamilton
- Start
- Oct 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of indocyanine green in non-small cell lung cancer (NSCLC), sponsored by St. Joseph's Healthcare Hamilton. Primary endpoints: Safety determined by the rates of adverse reactions to ICG dye, intra-operative adverse events, and post-operative complications at 2 years, Reproducibility at 2 years and 1 more. Planned start Oct 2017; status: withdrawn.
02
Drugs
indocyanine green
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02570958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02570958.